During the last session, KalVista Pharmaceuticals Inc (NASDAQ:KALV)’s traded shares were 0.41 million, with the beta value of the company hitting 0.84. At the end of the trading day, the stock’s price was $10.15, reflecting an intraday gain of 8.85% or $0.83. The 52-week high for the KALV share is $16.88, that puts it down -66.31 from that peak though still a striking 27.19% gain since the share price plummeted to a 52-week low of $7.39. The company’s market capitalization is $494.46M, and the average intraday trading volume over the past 10 days was 0.52 million shares, and the average trade volume was 397.89K shares over the past three months.
KalVista Pharmaceuticals Inc (KALV) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. KALV has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.91.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
KalVista Pharmaceuticals Inc (NASDAQ:KALV) trade information
KalVista Pharmaceuticals Inc (KALV) registered a 8.85% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 8.85% in intraday trading to $10.15, hitting a weekly high. The stock’s 5-day price performance is 6.95%, and it has moved by -15.91% in 30 days. Based on these gigs, the overall price performance for the year is 33.91%. The short interest in KalVista Pharmaceuticals Inc (NASDAQ:KALV) is 6.87 million shares and it means that shorts have 24.86 day(s) to cover.
The consensus price target of analysts on Wall Street is $20, which implies an increase of 49.25% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $20 and $28 respectively. As a result, KALV is trading at a discount of -175.86% off the target high and -97.04% off the low.
KalVista Pharmaceuticals Inc (KALV) estimates and forecasts
Statistics show that KalVista Pharmaceuticals Inc has outperformed its competitors in share price, compared to the industry in which it operates. KalVista Pharmaceuticals Inc (KALV) shares have gone down -10.18% during the last six months, with a year-to-date growth rate more than the industry average at 21.51% against 16.60. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -13.50% this quarter and then jump 40.48% in the quarter after that.
Meanwhile, a consensus of 7 analyst(s) estimates revenue growth to 15.98M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -20.06%. While earnings are projected to return 10.71% in 2024.
KALV Dividends
KalVista Pharmaceuticals Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
KalVista Pharmaceuticals Inc (NASDAQ:KALV)’s Major holders
KalVista Pharmaceuticals Inc insiders own 1.35% of total outstanding shares while institutional holders control 110.26%, with the float percentage being 111.77%. VR ADVISER, LLC is the largest shareholder of the company, while 175.0 institutions own stock in it. As of 2024-06-30, the company held over 6.25 million shares (or 14.3373% of all shares), a total value of $73.62 million in shares.
The next largest institutional holding, with 4.22 million shares, is of TANG CAPITAL MANAGEMENT LLC’s that is approximately 9.6783% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $49.7 million.
Also, the Mutual Funds coming in first place with the largest holdings of KalVista Pharmaceuticals Inc (KALV) shares are Smallcap World Fund and Vanguard Total Stock Market Index Fund . Data provided on Jun 30, 2024 indicates that Smallcap World Fund owns about 3.23 shares. This amounts to just over 7.47 percent of the company’s overall shares, with a $32.76 million market value. The same data shows that the other fund manager holds slightly less at 1.08, or about 2.51% of the stock, which is worth about $11.01 million.
